Cempra Inc (NASDAQ:CEMP) has earned an average recommendation of “Hold” from the eighteen brokerages that are covering the stock. Four analysts have rated the stock with a sell rating, nine have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $8.60.

CEMP has been the subject of several recent research reports. Roth Capital upgraded Cempra from a “neutral” rating to a “buy” rating and lowered their price target for the company from $8.00 to $2.50 in a report on Monday, February 27th. Vetr downgraded Cempra from a “strong-buy” rating to a “buy” rating and set a $3.43 price target for the company. in a report on Tuesday, February 21st. Zacks Investment Research upgraded Cempra from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a report on Tuesday, January 17th. Stifel Nicolaus reiterated a “hold” rating and issued a $4.00 price target on shares of Cempra in a report on Wednesday, March 1st. Finally, JPMorgan Chase & Co. reiterated a “hold” rating on shares of Cempra in a report on Thursday, January 12th.

In other Cempra news, Director Dov A. Md Goldstein sold 150,000 shares of the company’s stock in a transaction dated Wednesday, March 8th. The shares were sold at an average price of $3.55, for a total value of $532,500.00. Following the completion of the transaction, the director now directly owns 95 shares of the company’s stock, valued at approximately $337.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 17.80% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Bellevue Group AG purchased a new position in Cempra during the first quarter worth $619,000. TIAA CREF Investment Management LLC boosted its position in Cempra by 76.3% in the first quarter. TIAA CREF Investment Management LLC now owns 285,577 shares of the biotechnology company’s stock worth $1,071,000 after buying an additional 123,614 shares during the last quarter. Teachers Advisors LLC boosted its position in Cempra by 29.1% in the first quarter. Teachers Advisors LLC now owns 120,668 shares of the biotechnology company’s stock worth $453,000 after buying an additional 27,187 shares during the last quarter. Asset Management One Co. Ltd. purchased a new position in Cempra during the first quarter worth $106,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Cempra during the first quarter worth $187,000. 79.92% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/05/12/cempra-inc-cemp-receives-consensus-recommendation-of-hold-from-analysts.html.

Shares of Cempra (NASDAQ:CEMP) traded up 2.1950% during midday trading on Friday, hitting $4.0878. The stock had a trading volume of 101,572 shares. The stock’s market cap is $214.62 million. Cempra has a 12-month low of $2.55 and a 12-month high of $26.95. The stock has a 50-day moving average price of $3.88 and a 200-day moving average price of $5.40.

Cempra (NASDAQ:CEMP) last released its quarterly earnings data on Friday, April 28th. The biotechnology company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.16. The business had revenue of $4.87 million during the quarter, compared to the consensus estimate of $3.55 million. Cempra had a negative return on equity of 59.94% and a negative net margin of 678.72%. During the same period in the prior year, the firm posted ($0.61) EPS. Equities analysts forecast that Cempra will post ($1.06) earnings per share for the current year.

Cempra Company Profile

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

5 Day Chart for NASDAQ:CEMP

Receive News & Ratings for Cempra Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc and related companies with MarketBeat.com's FREE daily email newsletter.